US Edition#Navigating the Complex Terrain of Bexotegrast Pliant Therapeutics Halts BEACON-IPF Trial Amid Promising Indications
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
#Navigating the Complex Terrain of Bexotegrast Pliant Therapeutics Halts BEACON-IPF Trial Amid Promising Indications
In the constantly shifting landscape of pharmaceutical research, Pliant Therapeutics, Inc., based in South San Francisco, has recently made significant strides, only to find themselves pausing for reassessment. The company announced that it has discontinued its BEACON-IPF Phase 2b trial, which was evaluating the efficacy of bexotegrast in patients suffering from idiopathic pulmonary fibrosis (IPF). The decision to halt the trial was made after a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
